Cautious optimism in anticipation of hepatitis B curative therapies

Despite relative effectiveness of current hepatitis B therapies, there is still no curative agents available. The new emerging approaches hold promise to achieve cure and loss of hepatitis B surface antigen. Studies or clinical trials investigating new therapies remain small and either focus on pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Turshudzhyan, Alla, Tadros, Micheal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372785/
https://www.ncbi.nlm.nih.gov/pubmed/36159610
http://dx.doi.org/10.5501/wjv.v11.i4.212
_version_ 1784767461614157824
author Turshudzhyan, Alla
Tadros, Micheal
author_facet Turshudzhyan, Alla
Tadros, Micheal
author_sort Turshudzhyan, Alla
collection PubMed
description Despite relative effectiveness of current hepatitis B therapies, there is still no curative agents available. The new emerging approaches hold promise to achieve cure and loss of hepatitis B surface antigen. Studies or clinical trials investigating new therapies remain small and either focus on patients with low viral load and without hepatotoxic injury or patients with hepatitis D co-infection, which makes it challenging to assess their effectiveness and side effect profile in hepatitis B population.
format Online
Article
Text
id pubmed-9372785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-93727852022-09-23 Cautious optimism in anticipation of hepatitis B curative therapies Turshudzhyan, Alla Tadros, Micheal World J Virol Letter to the Editor Despite relative effectiveness of current hepatitis B therapies, there is still no curative agents available. The new emerging approaches hold promise to achieve cure and loss of hepatitis B surface antigen. Studies or clinical trials investigating new therapies remain small and either focus on patients with low viral load and without hepatotoxic injury or patients with hepatitis D co-infection, which makes it challenging to assess their effectiveness and side effect profile in hepatitis B population. Baishideng Publishing Group Inc 2022-07-25 2022-07-25 /pmc/articles/PMC9372785/ /pubmed/36159610 http://dx.doi.org/10.5501/wjv.v11.i4.212 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Letter to the Editor
Turshudzhyan, Alla
Tadros, Micheal
Cautious optimism in anticipation of hepatitis B curative therapies
title Cautious optimism in anticipation of hepatitis B curative therapies
title_full Cautious optimism in anticipation of hepatitis B curative therapies
title_fullStr Cautious optimism in anticipation of hepatitis B curative therapies
title_full_unstemmed Cautious optimism in anticipation of hepatitis B curative therapies
title_short Cautious optimism in anticipation of hepatitis B curative therapies
title_sort cautious optimism in anticipation of hepatitis b curative therapies
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372785/
https://www.ncbi.nlm.nih.gov/pubmed/36159610
http://dx.doi.org/10.5501/wjv.v11.i4.212
work_keys_str_mv AT turshudzhyanalla cautiousoptimisminanticipationofhepatitisbcurativetherapies
AT tadrosmicheal cautiousoptimisminanticipationofhepatitisbcurativetherapies

Ejemplares similares